(18.204.227.34) 您好!臺灣時間:2021/05/19 08:15
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:蔡國農
研究生(外文):Kuo-Nung Tsai
論文名稱:利用前瞻性世代追蹤研究探討非酒精性脂肪肝臟疾病於大腸直腸腺腫發生率之作用
論文名稱(外文):The Effect of Non-Alcoholic Fatty Liver Disease on the Incidence of Colorectal Neoplasm: a Prospective Cohort Follow-up Study
指導教授:陳秀熙陳秀熙引用關係
口試委員:廖朝聖嚴明芳邱瀚模
口試日期:2013-07-26
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:公共衛生碩士學位學程
學門:醫藥衛生學門
學類:公共衛生學類
論文種類:學術論文
論文出版年:2013
畢業學年度:101
語文別:英文
論文頁數:34
中文關鍵詞:非酒精性脂肪肝大腸直腸腺腫發生率世代追蹤研究
外文關鍵詞:Non-alcoholic fatty liver diseasecolorectal neoplasmincidencecohort study
相關次數:
  • 被引用被引用:0
  • 點閱點閱:140
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
背景 非酒精性脂肪肝病(NAFLD)和大腸直腸腺腫有著共同的危險因子,如肥胖,糖尿病和代謝症候群等。我們合理的推測,非酒精性脂肪肝疾病可能會增加大腸直腸腺腫的風險。然而,對於內視鏡檢查後的腫瘤發生影響仍不清楚,因此值得調查。
目的 調查NAFLD在調整其他干擾因子包括肥胖,糖尿病,代謝症候群等後,是否為經大腸鏡檢查為正常的世代其後續大腸直腸腺腫發生的危險因子。
方法 本研究是一前瞻性世代追蹤研究。於台灣北部某醫學中心,收集了接受健康檢查無疾病的世代。非酒精性脂肪肝診斷是依據超音波下脂肪肝之有無,追蹤這些世代後續大腸直腸腺腫的發生。 2004年1月至和2012年12月期間,共有53960名參與者進行了篩檢。受試者如果符合下列條件將被排除在外:(1)腹部超音波或大腸鏡檢查未在同一天進行,(2)B型肝炎或C型肝炎病毒血清標誌陽性,(3)男性每天消耗> 30克酒精和女性每天消耗> 20克,(4)存在慢性肝臟疾病,包括病毒性,毒物和自身免疫性肝病,(5)清腸準備不佳或不完整的大腸鏡檢查,(6)有大腸瘜肉或經大腸瘜肉切除病史,(7)有發炎性腸道疾病病史,或(8)大腸直腸癌病史。一共有15526名(7248名男性和8278名女性)進入最後的分析。本研究使用Poisson regression估計NAFLD對大腸直腸腺腫發生的相對危險性(Relative Risk, RR)。
結果 共有849人於後續追蹤期間被診斷出大腸直腸腺腫。大腸直腸腺腫易發生於男性,年老(>=50 歲),有脂肪肝,糖尿病,較高的血壓和異常血清三酸甘油酯的族群。大腸直腸腺腫的發生率在NAFLD組為15.5/1000人年,正常組11.6/1000人年。累積大腸直腸腺腫的發生率在NAFLD組高於無NAFLD組。男性和女性的趨勢是相似的。非酒精性脂肪肝患者有較高的累積大腸直腸腺腫風險。調整年齡,性別和個別代謝症候群因子後,大腸直腸腺腫和NAFLD之間的關係仍然顯著,其調整後RR為1.34 (95%信賴區間(Confidence Interval, CI)為1.13-1.60)。調整代謝症候群時,NAFLD仍然是大腸直腸腺腫的一個獨立的危險因子(調整後RR = 1.27(95%CI為1.03-1.56)。
結論 有非酒精性脂肪肝的族群其大腸直腸腺腫發生率較無非酒精性脂肪肝的族群高出34%,而且不會被代謝症候群或其個別因子如中央性肥胖(通過調整WC),低HDL所干擾。


Background Non-alcoholic fatty liver disease (NAFLD) and colorectal neoplasm share common risk factors, such as obesity, diabetes, and metabolic syndrome. It is reasonable to postulate that NAFLD may increase the risk of colorectal neoplasm. Its impact on incident neoplasm after negative colonoscopy, however, remains unclear and thus worthwhile of investigation.
Objectives We aimed to investigate the association between NAFLD and the risk of incident colorectal neoplasm in a negative colonoscopy cohort with adjustment for confounding factors, such as obesity, diabetes, and metabolic syndrome.
Methods This study is a prospective cohort follow-up study. We collected a healthy cohort which was initially free of colorectal neoplasm with evidence from colonoscopy in the health checkup setting from a medical center in northern Taiwan, defined the baseline status of study interests, NAFLD, based on abdominal ultrasonography at the recruited day, and prospectively followed the cohort for the incidence of colorectal neoplasm. During Jan 2004 and Dec 2012, a total of 53960 participants were screened. Subjects were excluded if the following criteria were met: (1) abdominal ultrasound or colonoscopy not conducted in the same day, (2) individuals with positive serologic markers of hepatitis B or hepatitis C virus, (3) men consuming >30 g of alcohol per day and women who consuming >20 g per day, (4) subjects with history of chronic liver disease, including viral, toxic and autoimmune liver diseases, (5) poor bowel preparation or incomplete colonoscopies, (6) subjects with a history of colorectal polypectomy, (7) individuals with inflammatory bowel disease, and (8) individuals with a history of colorectal cancer. There were a total of 15526 subjects (7248 men and 8278 women) in the final analysis. We used Poisson regression model to estimate the relative risk (RR) of NAFLD for developing colorectal neoplasm with adjustment for confounding factors in the whole cohort.
Results A total of 849 participants had incident colorectal neoplasm during the follow-up period. Subjects with incident colorectal neoplasm were more likely to be men, elderly age, and having NAFLD, DM, higher blood pressure and abnormal serum triglyceride level at baseline. The incidence of colorectal neoplasm in NAFLD group was 15.5/1000 person years as compared to 11.6/1000 person years in normal subject group. The cumulative colorectal neoplasm incidence for subjects with baseline NAFLD was higher than NAFLD-free subjects. The trend for male and female was similar. A higher cumulative risk of neoplasm among patient with NAFLD compared to those without. After adjustment of age, sex, and individual metabolic syndrome components, the relationships between colorectal neoplasm and NAFLD remained statistically significant (aRR=1.34, 95% CI: 1.13-1.60). When the adjustment was made for metabolic syndrome rather than its components, NAFLD was still an independent risk factor on incident colorectal neoplasm (aRR=1.27, 95% CI: 1.03–1.56).
Conclusions Subjects with NAFLD had a 34% higher colorectal neoplasm incidence compared with those without NAFLD, which is independent from metabolic syndrome components such as central obesity (by adjustment of WC), and low HDL.


口試委員會審定書 ………………………………………… i
致謝 ………………………………………………………… ii
中文摘要 …………………………………………………… iii
Abstract ……………………………………………………… v
Practicum Unit Features …………………………………… 1
Introduction ………………………………………………….. 3
Literature review…………..…………………………………. 6
Material and Methods ……………………………………….. 10
Study design …………………………………………………. 10
Participants ………………………………………………….. 10
Measurements ……………………………………………….. 11
Diagnosis of non-alcoholic fatty liver disease ………………. 12
Colonoscopy examination …………………………………… 13
Statistical analysis …………………………………………… 14
Results ……………………………………………………….. 16
Discussion …………………………………………………….18
References…………………………………………………… 31


1.Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427.
2.Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR, 2007
3.Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-87.
4.Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532
5.Winawer SJ, Zauber AG, Ho MN, O''Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977-81.
6.Zauber AG, Winawer SJ, O''Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687-96.
7.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16.
8.Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5-10.
9.Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, Yang YC, Wu CL, Chang CJ. The role of Hepassocin in the development of nonalcoholic fatty liver disease. J Hepatol. 2013: S0168-8278(13)00414-5.
10.Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68(1):323-8.
11.Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005 ;7(3):211-7.
12.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-19.
13.Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50.

14.Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85.
15.Foster T, Anania FA, Li D, Katz R, Budoff M. The Prevalence and Clinical Correlates of Nonalcoholic Fatty Liver Disease (NAFLD) in African Americans: The Multiethnic Study of Atherosclerosis (MESA). Dig Dis Sci. 2013;58(8):2392-8.
16.Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61.
17.Nobili V, Reale A, Alisi A, Morino G, Trenta I, Pisani M, Marcellini M, Raucci U. Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. Dig Liver Dis. 2009;41(10):749-52.
18.Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012 ;51(4):305-12.
19.Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13(47):6419-24.
20.Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, Choi PC, Chan AW, So WY, Chan FK, Sung JJ, Chan HL. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008;103(7):1682-8.
21.Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28 Suppl 1:11-7.
22.Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic Fatty liver disease in a nonobese chinese population: the zhejiang zhenhai study. Am J Gastroenterol. 2013;108(8):1299-304.
23.Hsu CS, Kao JH. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J Formos Med Assoc. 2012;111(10):527-35.
24.Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol. 2007;22(9):1482-9.
25.Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A; Asia-Pacific Working Party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007 ;22(6):794-800.
26.Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Won KH, Jin W. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25(3):562-7.
27.Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, Strasser M, Brunner E, Heuberger A, Hohla F, Steinwendner J, Patsch W, Datz C. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270(1):41-9.
28.Touzin NT, Bush KN, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2011;4(3):169-76.
29.Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60(6):829-36.
30.Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27(1):91-5.
31.Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 24-30;366(9491):1059-62.
32.Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound. 1996;24(1):25-9.
33.Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, Torella R, Persico M. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38(7):485-9.
34.Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol. 1991;86(8):946-51.
35.Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95:3053–63.
36.Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002;12: 1–9.
37.Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107(1):28-36.
38.Schiel R, Müller UA, Braun A, Stein G, Kath R. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res. 2005;10(8):339-44.
39.Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86(3):s836-42.
40.Graif M, Yanuka M, Baraz M, Blank A, Moshkovitz M, Kessler A, Gilat T, Weiss J, Walach E, Amazeen P, Irving CS. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest. Radiol. 2000; 35: 319–24.
41.Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002 5;99(3):1521-6.
42.Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001;276(21):18075-81.
43.Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ, Tanabe T, Inoue H, Arata J, Jetten AM. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J Biol Chem. 1999;274(41):29138-48.
44.Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top